Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.

abstract：:This study describes our institution's experience using whole brain radiation therapy (WBRT) to treat patients with acute myelogenous leukemia (AML) presenting with hyperleukocytosis. After approval by the institutional review board, we identified patients with AML and hyperleukocytosis using hospital records. The pri...

journal_title：Leukemia & lymphoma

authors： Ferro A,Jabbour SK,Taunk NK,Aisner J,Cohler A,Somalya S,Goyal S

更新日期：2014-01-01 00:00:00

abstract：:The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure f...

journal_title：Leukemia & lymphoma

authors： Stahl M,Tallman MS

更新日期：2019-12-01 00:00:00

abstract：:The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

journal_title：Leukemia & lymphoma

authors： Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

更新日期：2002-11-01 00:00:00

abstract：:The in vitro proliferative response of purified B-chronic lymphocytic leukemia (B-CLL) lymphocytes cultured in the presence of soluble CD23 (sCD23) with or without IL2 was compared to the responses induced by phorbol 12-myristate 13-acetate (PMA), Staphylococcus aureus strain Cowan I (SAC), IL1, IL2, IL4, IL6 and the ...

journal_title：Leukemia & lymphoma

authors： Brizard A,Morel F,Lecron JC,Dreyfus B,Brizard F,Barra A,Preud'homme JL

更新日期：1994-07-01 00:00:00

abstract：:Central nervous system (CNS) relapse is a challenging complication in patients with diffuse large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom prophylactic treatment may play a significant role, is critical. We calculated the incidence of CNS relapse and evaluated the risk factors...

journal_title：Leukemia & lymphoma

authors： Chihara D,Oki Y,Matsuo K,Onoda H,Taji H,Yamamoto K,Morishima Y

更新日期：2011-12-01 00:00:00

abstract：:Thrombopoietin (TPO) has been successfully used to stimulate megakaryocyte progenitor proliferation and platelet production both in vitro and in vivo. We and other investigators have found that TPO also stimulates normal marrow colony-forming unit granulocyte-macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E...

journal_title：Leukemia & lymphoma

authors： Ferrajoli A,Talpaz M,Kurzrock R,Harris D,Van Q,Estey EH,Estrov Z

更新日期：1998-07-01 00:00:00

abstract：:BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

journal_title：Leukemia & lymphoma

authors： Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

更新日期：2013-06-01 00:00:00

abstract：:Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

journal_title：Leukemia & lymphoma

authors： Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

更新日期：2006-06-01 00:00:00

abstract：:The human retinoblastoma gene product which is involved in cell cycle control and also acts as a transcriptional repressor of genes involved in growth control, is constitutively expressed as a phosphoprotein in normal hemopoietic cells. Abnormalities of the retinoblastoma gene expression leading to loss of protein exp...

journal_title：Leukemia & lymphoma

authors： Zhu YM,Haynes AP,Keith FJ,Russell NH

更新日期：1995-06-01 00:00:00

abstract：:Prognostic factors in acute lymphoblastic leukemia (ALL) are used for treatment stratification of ALL. Definition of simple parameters such as the presence or absence of peripheral leukemic cells after one week of treatment could help for stratification. A retrospective study was conducted on 79 previously untreated a...

journal_title：Leukemia & lymphoma

authors： Legrand O,Marie JP,Cadiou M,Blanc C,Ramon S,Zittoun R

更新日期：1994-11-01 00:00:00

abstract：:The aims of this study were: 1) to identify the type of bcl-2 rearrangement in a Brazilian group of FL patients and 2) to correlate it to clinical features, International Prognostic Index (IPI), histological subtype, response to treatment and clinical outcome. We reviewed the diagnosis of 48 patients with FL and inves...

journal_title：Leukemia & lymphoma

authors： Colleoni GW,Duarte LC,Kerbauy FR,Noguti MA,Da Silva ID,Otsuka AY,Alves AC,Silva MR

更新日期：2004-02-01 00:00:00

abstract：:The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

journal_title：Leukemia & lymphoma

authors： Reinke EN,Bera S,Diamond AM

更新日期：2015-04-01 00:00:00

abstract：:Immune suppression is a hallmark of multiple myeloma (MM), but data on soluble factors involved in the fate of immune effector cells are limited. The CXCR3-binding chemokine monokine induced by interferon-gamma (MIG/CXCL9) has been associated with tumor progression, immune escape, and angiogenesis in several malignanc...

journal_title：Leukemia & lymphoma

authors： Bolomsky A,Schreder M,Hübl W,Zojer N,Hilbe W,Ludwig H

更新日期：2016-11-01 00:00:00

abstract：:The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymp...

journal_title：Leukemia & lymphoma

authors： Segman Y,Ribakovsky E,Avigdor A,Goldhecht Y,Vainstein V,Goldschmidt N,Harlev S,Horwitz N,Gutwein O,Gurion R,Itchaki G,Abadi U,Nemets A,Sofer O,Zektser M,Tadmor T,Dally N,Filanovsky K,Leiba M,Sarid N,Benyamini N,

更新日期：2021-01-01 00:00:00

abstract：:Interferon-gamma (IFN-gamma) exhibits various properties including antigrowth activity in neoplastic and normal cells and regulatory roles in immune responses and hematopoiesis, but studies of IFN-gamma effects on human megakaryopoiesis have been inconclusive. Recently we have used serum-free culture of purified CD34+...

journal_title：Leukemia & lymphoma

authors： Tsuji K,Muraoka K,Nakahata T

更新日期：1998-09-01 00:00:00

abstract：:Two important syndromes of hemophagocytic lymphohistiocytosis (HLH) have to be considered in infants and young children with recurrent fever, organomegaly and cytopenias. Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infil...

journal_title：Leukemia & lymphoma

authors： Dürken M,Finckenstein FG,Janka GE

更新日期：2001-03-01 00:00:00

abstract：:Immune mechanisms superimposed to the myeloablative conditioning regimens exert an additional powerful effect in eradicating leukemia and in achieving immunological control of minimal residual disease. The impact of GVHD-independent GVL has been evaluated to be absent, or near absent, in ALL, about 30% in AML and abou...

journal_title：Leukemia & lymphoma

authors： Marmont AM

更新日期：1993-01-01 00:00:00

abstract：:Graft-versus-host disease (GVHD) represents the major barrier to successful allogeneic bone marrow transplantation. Positive and negative selection studies have unequivocally demonstrated that donor T cells are responsible for the induction phase of GVHD. Inhibition of the early steps of T cell antigen recognition lea...

journal_title：Leukemia & lymphoma

authors： Schlegel PG,Chao NJ

更新日期：1996-09-01 00:00:00

abstract：:A kindred with familial leukemia is described in which three members are affected by leukemia in three consecutive generations. One of these members had Philadelphia positive chronic myeloid leukemia (CML) and other two had precursor B acute lymphoblasticleukemia (ALL)--Philadelphia negative. All three of them shared ...

journal_title：Leukemia & lymphoma

authors： Kuruvilla J,Gupta V,Gill KS,Lipton JH

更新日期：2003-02-01 00:00:00

abstract：:We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...

journal_title：Leukemia & lymphoma

authors： Chaoui D,Peffault De Latour R,Legrand O,Marie JP

更新日期：2005-03-01 00:00:00

abstract：:Hepatitis due to reactivation of hepatitis B virus is an important cause of liver-related morbidity and mortality in hepatitis B surface antigen (HBsAg) positive patients undergoing autologous hematopoeitic cell transplantation. With the recent introduction of sensitive serum HBV DNA quantitation assay, the diagnosis ...

journal_title：Leukemia & lymphoma

authors： Ma SY,Lau GK,Cheng VC,Liang R

更新日期：2003-08-01 00:00:00

abstract：:Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias...

journal_title：Leukemia & lymphoma

authors： Bose P,Verstovsek S

更新日期：2020-08-01 00:00:00

abstract：:To define the specific genetic alterations in nasal natural killer/T-cell lymphoma (N-NK/T-L), the assay of restriction landmark genomic scanning (RLGS), a genome-wide method, was used to investigate a pair of genomic DNA from N-NK/T-L cells and peripheral blood leukocytes of the same patient. The intensified spots in...

journal_title：Leukemia & lymphoma

authors： Ye Y,Li T,Zhang B,Guo Z

更新日期：2007-01-01 00:00:00

abstract：:The de novo megakaryocytic leukemia fulfilling the FAB criteria is still an uncommonly recognized variant of acute leukemia. Many studies have shown that the megakaryocytic leukemic events may occur at a pluripotent stem cell level and clinical observations reveal that the megakaryocytic leukemias are diverse entities...

journal_title：Leukemia & lymphoma

authors： Ryo R,Yasunaga M,Saigo K,Yamaguchi N

更新日期：1992-11-01 00:00:00

abstract：:The significant clinical activity of lenalidomide in relapsed CLL was first described several years ago. Since then the problems of tumor flare and tumor lysis have emerged, and upfront single agent studies have reported response rates that were perhaps a little disappointing. Interest in elucidating the place of lena...

journal_title：Leukemia & lymphoma

authors： Brown JR

更新日期：2010-08-01 00:00:00

abstract：:Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

journal_title：Leukemia & lymphoma

authors： Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

更新日期：2018-02-01 00:00:00

abstract：:Clinical observation and laboratory evidence suggest that immune mechanisms play an important role in the natural control of evolution of the Ph+ clone in chronic phase as well as during progression of chronic myelogenous leukemia (CML). The understanding of these mechanisms could facilitate development of innovative ...

journal_title：Leukemia & lymphoma

authors： Selleri C,Maciejewski JP

更新日期：2000-04-01 00:00:00

abstract：:MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

journal_title：Leukemia & lymphoma

authors： Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

更新日期：2021-01-01 00:00:00

abstract：:Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease. An association between thymic epithelial neoplasms and MG is well known. However, it is rarely associated with hematologic malignancies. In particular, very few cases of lymphoblastic lymphoma involving the thymus and MG have been reported. Here w...

journal_title：Leukemia & lymphoma

authors： Uner AH,Abali H,Engin H,Akyol A,Ruacan S,Tan E,Güllü I,Altundağ K,Güler N

更新日期：2001-07-01 00:00:00

abstract：:PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

journal_title：Leukemia & lymphoma

authors： Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

更新日期：2013-12-01 00:00:00